z-logo
open-access-imgOpen Access
Selective toxicity of Caspian cobra ( Naja oxiana ) venom on liver cancer cell mitochondria
Author(s) -
Enayatollah Seydi,
Shabnam Babaei,
Amir Fakhri,
Jalal Pourahmad
Publication year - 2017
Publication title -
asian pacific journal of tropical biomedicine/asian pacific journal of tropical biomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.507
H-Index - 61
eISSN - 2588-9222
pISSN - 2221-1691
DOI - 10.1016/j.apjtb.2017.01.021
Subject(s) - cobra , mitochondrion , venom , apoptosis , chemistry , cytotoxicity , reactive oxygen species , toxicity , liver cancer , cytochrome c , snake venom , pharmacology , microbiology and biotechnology , biochemistry , biology , cancer research , hepatocellular carcinoma , in vitro , computer science , programming language , organic chemistry
Objective: To explore the cytotoxicity effects of Caspian cobra (Naja oxiana or N. oxiana) venom on hepatocytes and mitochondria obtained from the liver of HCC rats.Methods: In this study, HCC was induced by diethylnitrosamine (DEN), as an initiator, and 2-acetylaminofluorene (2-AAF), as a promoter. Rat liver hepatocytes and mitochondria for evaluation of the selective cytotoxic effect of N. oxiana venom were isolated and mitochondria and cellular parameters related to apoptosis signaling were then determined.Results: Our results showed a raise in mitochondrial reactive oxygen species (ROS) level, swelling in mitochondria, mitochondrial membrane potential (Δψm) collapse and release of cytochrome c after exposure of mitochondria only isolated from the HCC group with the crude venom of the N. oxiana (12.5, 25, and 50 μg/mL). This crude venom also induced caspase-3 activation (P < 0.001) in the hepatocytes obtained only from the HCC rat liver.Conclusions: Based on the over all results, we suggested that N. oxiana may be considered as a promising complementary therapeutic agent for the treatment of HCC

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here